anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a Chinese herbal medicine, particularly health face beautifying powder which has treatment and health care effects on hemochromatosis and endocrine dyscrasia of the human bodym and has an elimination effect on facial acnes and color spots. The powder is prepared from 18 Chinese herbal medicines of arnebia root, sophora fruit, rehmannia root, chrysanthemum, green tangerine peel, figwort root, root-bark of tree peony, angelica, etc. through grinding into powder, preparing into medicinal powder and packaging. The medicine formulation can also be made into oral medicinal liquids, pills, tablets or capsule preparations. The powder has the functions of clearing the liver, coursing the liver, eliminating liver accumulation, removing liver poison, dispersing liver wind, cooling blood, promoting circulation of blood, removing blood stagnancy, eliminating blood accumulation, dredging blood depression, killing blood viruses, expelling blood stasis, engendering new blood, reducing internal heat, and regulating and tonifying internal deficiency, etc. The present invention has the effects that the source liver is washed to obtain blood, and the blood is clarified and purified to obtain fresh red blood; the function of the disorder endocrine can be recovered; facial black spots, chloasmata, sunburn, freckles, cyasma, bad skin color, blueish yellow skin, dark skin, rough skin, acnes, comedo prints, etc. automatically disappear; hepatopathy and internal heat are immediately relieved. The present invention is a new approach for solving fundamental causes.
For patients randomized to the control group, EVT has to be completed within 24 hours of stroke onset. The choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
Cervical cancer (CC) has been a hot topic in the field of gynecological cancer due to its high morbidity and mortality. As one of the major components, tumor-associated macrophages (TAMs) play a crucial role in the tumor microenvironment (TME), differentiating into M1 and M2 phenotypes under the influence of various cytokines, with a predominance of the M2 phenotype among TAMs. Notably, the functions of these two phenotypes are almost opposite. M1 macrophages promote inflammation and inhibit tumor development, while M2 macrophages tend to suppress the immune response and promote tumor growth. Additionally, TAMs can influence tumor invasion, metastasis and immune regulation through interacting with various lymphocytes and cytokines. Numerous studies have demonstrated that TAMs can be used as prognostic markers for CC, and as therapeutic targets in clinical setting. A deeper comprehension of interactions between TAMs and CC, achieved by integrating findings and conclusions from various studies, is conducive to the discovery of new directions for research and new perspectives for clinical treatment.
Basic triphenylalkene derivatives of formula I are prepared by reacting the corresponding triphenyl halide with an aminoethanol substituted by R1 and R2. The substituents in formula I have the meaning given in Patent Claim 1. The triphenyl halides are employed in the form of their (Z)-isomer or (E)-isomer or an isomer mixture. When an isomer mixture is employed, a mixture of the isomers of the compound of formula I is obtained. This mixture can be separated by fractional crystallisation of the salts of the compounds of the formula I in an aqueous acidic solution. The compounds of formula I exhibit an anti-oestrogenic action. <IMAGE>
Sexual arousal difficulties are common among women, affecting approximately 22% of women between the ages of 18 and 59 (Laumann, Paik \& Rosen, 1999). Although there are evidence-based psychological treatments available for women with orgasmic and pain disorders, there are currently no empirically-supported treatments for women with acquired Sexual Arousal Disorder (FSAD). Moreover, there have been numerous attempts to find evidence for a pharmacological agent effective at treating women's sexual arousal complaints; however, to date these studies have been inconclusive. Given the significant role that sexual health plays in quality of life, the fact that effective psychological treatments for women's sexual dysfunction are not widely available, and the fact that wait-lists to see health care professionals with expertise in the area of sexual dysfunction are often unwieldy, there is a need to establish brief, evidence-based approaches to treat women's acquired FSAD. Psychological therapy in a group format is a standard practice at the BC Centre for Sexual Medicine. However, in this study we would like to collect information from participants that would help us in determining the specific efficacy of the PED as well as identifying demographic or participant variables that might predict a positive response to the PED. Because we are using this information to determine the treatment's efficacy and because we will use this information as the basis for a publication, we deem this to be a research trial in which ethics review is necessary.

OBJECTIVES: We have recently developed and tested a new psychoeducational treatment (PED) for the treatment of FSAD due to early-stage gynecologic cancer treatment. Our data show this PED to significantly improve self-reported sexual desire, arousal, mood, relationship distress, and quality of life. We are currently testing the efficacy of this PED in a larger sample of cancer survivors with FSAD. The goal for this study is to test our PED in a group format for women who are currently seeking treatment at the BC Centre for Sexual Medicine for FSAD. By testing the efficacy of the PED administered in a group format, we hope to establish some preliminary data supporting the use of brief psychoeducational interventions for women. These pilot data will be used in a future larger-scale trial that involves randomization to group PED or a control condition in order to more definitively establish the PED efficacy.
Standard care: patients will continue adalimumab maintenance treatment of 40mg per 2 weeks. Treatment decisions are made at the discretion of the treating physician.
The method for the intensive treatment of schizophrenia with the continuous course and suicidal behavior comprises the use of Rispolept with accompanying electrically induced sleep. The daily oral dose of Rispolept increases within the week up to the average dose 5 mg daily. The sleep is induced in 1.5 hours after the morning dose of Rispolept is taken. The electrodes are mounted near the eyes and behind the ears. In the course of the treatment, the current is augmented from 15 to 20 mA, the pulse frequency û from 5 to 120 Hz, the pulse duration û from 0.2 to 0.5 ms, the duration of the procedure û from 20 to 90 min. The overall course of the treatment comprises 15 daily sessions.
A method for distributing a prescription pharmaceutical product includes recording a unique identifier in a database that identifies a medium and a prescription pharmaceutical product associated with the medium. The database is provisioned with criteria that establish different potential values for the medium. Thus, the medium has a variable value that varies according to the criteria provisioned in the database. A holder of the medium then presents the medium to a provider of the prescription pharmaceutical product. Upon receipt the medium, the provider communicates the unique identifier associated with the medium. Based on the unique identifier of the medium and the variable value criteria provisioned in the database, the value of the medium is determined and communicated to the provider. The holder then utilizes the determined value to purchase the prescription pharmaceutical product associated with the medium.
<P>PROBLEM TO BE SOLVED: To provide a daily life watching system capable of identifying and acquiring event information about lives of a plurality of watching target persons and protecting privacy while allowing reaction in the case of emergency.  <P>SOLUTION: A living person 103 wears a wearable living body information detection sensor 2. Sensors 1-4 such as a living person detection sensor acquire a living person ID from the wearable living body information detection sensor 2 when a living event of the living person 103 is detected. A home server 5 creates event information with the living person ID based on the information transmitted from these sensors 1-4, and accumulates the information in a living person event DB 720 in a center server 7. The home server 5 generates perusal permission information based on input operation by the living person 103 and transmits it to the center server 7. The home server 5 generate perusal permission information in emergency. The center server 7 refers to a DB perusal terminal 8 for the perusal permission information to provide a living event DB 720.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Patients with interferon receptor level not down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 48th week.
A method for the complex processing of the linden inflorescences provides for the successive extraction of the air dry raw material with the solvents of the various polarity, in particular the hydrophobic and hydrophilic organic solvents and the water producing the lipophilic and hydrophilic extracts followed by the removal of the solvents. In succession, the lipophilic complex, the phenolic complex, and the sum of polysaccharides are obtained. The liquefied gas such as difluorochloromethane is used as the hydrophobic solvent for producing the lipophilic complex. The extraction temperature is 10-50 °С, preferably 30-40 °С at a 1:5 - 1:50 ratio of raw material : extractant (preferably 1:10 - 1:30). The duration of the extraction is at least 2 hours. С-С, aliphatic alcohols, preferably. 20-90% ethanol, are used as the hydrophilic solvent for producing the phenolic complex. The extraction cake : extractant ratio is 1:10 - 1:20. The duration of the extraction is 2-24 hours. The sum of polysaccharides is obtained upon extracting the cake with the water at a 1:10 - 1:50 ratio of cake : extractant, preferably 1:20 - 1:30 at the temperature of 60-100 °С, preferably 70-80 °С upon constant stirring for 1-12 hours, preferably 2-6 hours.
Participants will have a sweet almond oil active comparator elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new active comparator elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
Up to 90 patients with Chronic IBD will be enrolled, with the goal of having three arms of 30 subjects in each group who are eligible for evaluation.

This exploratory trial is designed to estimate the effect of ginger exosomes or curcumin on IBD symptoms compared to ginger exosomes plus curcumin. In this prospective and randomized study the main focus is to compare exosomes alone, curcumin, and exosomes plus curcumin. Three primary stratification factors race (white and black), gender and type of IBD (CD and UC) will be used. plan Zelen's (1974) method will be used to avoid imbalance allocation within each stratum. A block size of 4 will be used. We plan to enroll all eligible patients visiting the clinic, as well as eligible patients referred from other gastroenterologists. All eligible visiting our clinic will be enrolled. By enrolling consecutive patients, we reduce selection bias. A patient will be enrolled only once.

The most important aim of this study is to compare the IBD symptoms in exosomes alone and exosomes plus curcumin groups of patients. The symptomatology will be measured in each group and compared to the self-reported score. We will use the incidence rate of bloody stool to justify the sample size. With the combination treatment (ginger exosomes plus curcumin as compared to curcumin alone) we hope to reduce symptoms by at least 30%. Using a two sample one-sided t test for comparing mean differences in Inflammatory Bowel Disease Questionnaire, with 30 subjects in each group and using alpha=5%, we will have 80% power to detect effect size of 0.65 Standard Deviation, which is a large effect size (Cohen, 1988).. When the reduction in sample size due to missing data or other reasons, we will have reduced power to detect the difference in two groups.
PURPOSE: A composition for the prevention and treatment of arteriosclerosis containing a novel compound of stereocalpin-A is provided to suppress the expression of VCAM-1 and ICAM-1 induced by TNF-alpha due to the incapability of signal transduction to MAP kinse, Akt, and NF-kB by the suppression of the ROS production. CONSTITUTION: A pharmaceutical composition for the prevention and treatment of arteriosclerosis comprises stereocalpin-A represented by chemical formula 1 as an active ingredient. The stereocalpin-A represented by the chemical formula 1 is contained at 0.01-10 parts by weight based on 100 parts by weight of composition. The stereocalpin-A represented by chemical formula 1 suppresses the expression of cell adhesion molecules which induces the TNF-alpha. The cell adhesion molecules are ICAM-1 or VCAM-1. The stereocalpin-A is originated from Ramalina terebrata.
Do not administer unless solution is clear and container is undamaged. Discard unused portion (see DOSAGE AND ADMINISTRATION).

Etomidate injection is intended for administration only by the intravenous route (see CLINICAL PHARMACOLOGY). The dose for induction of anesthesia in adult patients and in pediatric patients above the age of ten (10) years will vary between 0.2 mg/kg and 0.6 mg/kg of body weight, and it must be individualized in each case. The usual dose for induction in these patients is 0.3 mg/kg, injected over a period of 30 to 60 seconds. There are inadequate data to make dosage recommendations for induction of anesthesia in patients below the age of ten (10) years; therefore, such use is not recommended. Geriatric patients may require reduced doses of etomidate.

Smaller increments of intravenous etomidate may be administered to adult patients during short operative procedures to supplement subpotent anesthetic agents, such as nitrous oxide. The dosage employed under these circumstances, although usually smaller than the original induction dose, must be individualized. There are insufficient data to support this use of etomidate for longer adult procedures or for any procedures in pediatric patients; therefore, such use is not recommended. The use of intravenous fentanyl and other neuroactive drugs employed during the conduct of anesthesia may alter the etomidate dosage requirements. Consult the prescribing information for all other such drugs before using.
Parkinson's disease (PD) is recognized as the second most common neurodegenerative disease worldwide. Even if PD etiopathogenesis is not yet fully understood, in recent years, it has been advanced that a chronic state of inflammation could play a decisive role in the development of this pathology, establishing the close link between PD and neuroinflammation. In the broad panorama of inflammation and its several signaling pathways, the C-C chemokine receptor type 1 (CCR1) could play a key pathogenic role in PD progression, and could constitute a valuable target for the development of innovative anti-PD therapies. In this study, we probed the neuroprotective properties of the CCR1 antagonist BX471 compound in a mouse model of MPTP-induced nigrostriatal degeneration. BX471 treatments were performed intraperitoneally at a dose of 3 mg/kg, 10 mg/kg, and 30 mg/kg, starting 24 h after the last injection of MPTP and continuing for 7 days. From our data, BX471 treatment strongly blocked CCR1 and, as a result, decreased PD features, also reducing the neuroinflammatory state by regulating glial activation, NF-κB pathway, proinflammatory enzymes, and cytokines overexpression. Moreover, we showed that BX471's antagonistic action on CCR1 reduced the infiltration of immune cells, including mast cells and lymphocyte T activation. In addition, biochemical analyses carried out on serum revealed a considerable increase in circulating levels of CCR1 following MPTP-induced PD. In light of these findings, CCR1 could represent a useful pathological marker of PD, and its targeting could be a worthy candidate for the future development of new immunotherapies against PD.
FIELD: microbiology. SUBSTANCE: new strain of classic swine plague virus multiplicating at high infectious activity 5.0-6.5 lgBOE 5   0 /ml in transplanted cell cultures and showing high thermoresistance as compared with that of the strain ЛК-ВНИИВВиМ and retaining immunogenicity. Strain "ЛК-К" classic swine plague is deposited in Collection of ВНИИВВиМ at N 1842. Strain is obtained by limit dilution cloning method and selection of obtained clones by trait - multiplication at the high titer in transplanted cell cultures. Cloning is carried out by limit dilution method for 5 passages. As a result, the clone is isolated accumulating in transplanted cell cultures at titers 5.5-7.0 lgBOE 5   0 /ml. Stability of this trait is retained for 50 passages (observation period). Obtained virus clone is designed as "ЛК-К". EFFECT: preparing new strain indicated above. 1 tbl
Pretest: The newborn connected to nCPAP will be placed in the supine position and slight extension position on the neck of the newborn to ensure airway patency. The first saliva sample will be taken to measure cortisol level in the 30th minute after the first cry from the newborn who is connected to nasal CPAP. Immediately after the saliva sample is taken in pretest group, the stress level determined by using the "neonatal stress scale", vital signs (respiration, heart rate, oxygen saturation), saliva sample collection time will be recorded on the chart.
The present invention discloses a functional polypeptide. The functional peptide is 1) a polypeptide having the amino acid sequence as shown in SEQ ID No. 1; or 2) a polypeptide having the same or similar function after substitution, deletion or addition of one or several of the amino acids in the amino acid sequence shown in SEQ ID No. 1. The present invention further discloses a use of the functional polypeptide. The functional polypeptide has a function of preventing and treating pulmonary fibrosis.
Study meals were administered in commonly consumed serving sizes (3 hard-boiled eggs) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
Electrical stimulation (ES) is used by physical therapists during treatment of many conditions including muscle weakness and pain. Neuromuscular electrical stimulation (NMES) is used to produce strength gains, but it is uncomfortable. The discomfort is thought to limit its acceptability by patients. Transcutaneous electrical stimulation (TENS) is the application of ES for pain relief. The intensity of TENS is strong but comfortable. The nervous system modulates pain in many ways, and one way that it can inhibit pain is through conditioned pain modulation; the "pain inhibits pain" phenomenon. Painful experiences can elicit inhibitory mechanisms that actually reduce pain. This study is designed to demonstrate that NMES elicited muscle contractions produce pain relieving effects that will benefit patients over and above the strengthening effects. Participants will be healthy young (18-30 years of age) who will rate their pain and undergo bilateral quantitative sensory testing of pressure pain over the right quadriceps tendon. They will experience three conditions: volitional contractions at 20 percent of the maximum voluntary isometric contraction (MVIC) force, electrically elicited contractions at 20 percent MVIC, and noxious electrical stimulation (NXES) at maximum tolerated intensity applied to the patella to prevent muscle contraction. Ten contractions or trains of stimulation will be applied at a ratio of 10 seconds on 50 seconds off to replicate the typical application of NMES for muscle strengthening. The order of the conditions will comprise: volitional contractions and NXES will be applied in a random order followed by NMES contractions. NMES was applied last to reduce any influence of muscle fatigue. Pressure pain thresholds (PPT) will be measured before and after each condition in both knees and the middle finder by applying pressure at a rate of 30 kilopascal/s. Participants will indicate immediately when the pressure turns to pain and the pressure will be recorded as their pain threshold. This will be repeated 3 times and the average of the last 2 measurements will be used in the analysis. Participants will rate their pain during the conditions using an 11-point visual analog scales in which 0= no pain and 10= the worst pain imaginable. Testing will take place over two sessions, in the Motion Analysis Laboratory of the University of New England separated by at least one hour. In session 1, participants will be familiarized with any procedures that could cause pain including pressure pain threshold testing, NMES elicited muscle contractions and noxious stimulation. The MVIC force of the quadriceps will also be measured and used to determine the goal force output for the volitional and electrically elicited contractions of 20 percent MVIC. In session 2, participants will undergo the testing procedures, each separated by at least 1 hour.
Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
Intervention: Usual and customary care. No additional therapy will be initiated during the 1-year study.
BACKGROUND: Short-lasting unilateral neuralgiform headache attacks (SUNHA) have the features of both short-lasting unilateral neuralgiform pain, such as trigeminal neuralgia or stabbing headache, and associated trigeminal autonomic symptoms, such as paroxysmal hemicrania or cluster headache. Recognizing and adequately treating SUNHA is essential but current treatment methods are ineffective in treating SUNHA.
METHODS: We reviewed the changes in the concept of short-lasting unilateral neuralgiform headache attacks and provide a narrative review of the current medical and surgical treatment options, from the first choice of treatment for patients to treatments for selective intractable cases.
RESULTS: Unlike the initial impression of an intractable primary headache disorder affecting older men, SUNHA affects both sexes throughout their lifespan. One striking feature of SUNHA is that the attacks are triggered by cutaneous or intraoral stimulation. The efficacy of conventional treatments is disappointing and challenging, and preventive therapy is the mainstay of treatment because of highly frequent attacks of a very brief duration. Amongst them, lamotrigine is effective in approximately two-third of the patients with SUNHA, and intravenous lidocaine is essential for the management of acute exacerbation of intractable pain. Topiramate, oxcarbazepine and gabapentin are considered good secondary options for SUNHA, and botulinum toxin can be used in selective cases. Neurovascular compression is commonly observed in SUNHA, and surgical approaches, such as neurovascular compression, have been reported to be effective for intractable cases.
CONCLUSIONS: Recent advances in the understanding of SUNHA have improved the recognition and treatment approaches for this unique condition.